비교리스트

 카트 문의
시장보고서
상품코드
1656920

인플루엔자 백신 : 시장 인사이트, 경쟁 구도, 시장 예측(-2032년)

Influenza Vaccine - Market Insights, Competitive Landscape, and Market Forecast - 2032
발행일: | 리서치사: DelveInsight | 페이지 정보: 영문 150 Pages | 배송안내 : 2-10일 (영업일 기준)

    
    
    




■ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송일정은 문의해 주시기 바랍니다.

인플루엔자 백신 시장 규모는 2024년에 82억 4,744만 달러를 기록했습니다. 2032년까지 139억 5,082만 달러에 이를 것으로 예측되며, 2025-2032년의 예측 기간에 CAGR 6.87%로 성장할 것으로 전망됩니다. 인플루엔자 백신 접종에 대한 요구는 주로 기침과 재채기를 통해 감염되는 튀김에 의한 바이러스의 확산으로 인한 전염병의 전염에 의해 촉진되고 있습니다. 인플루엔자 백신 채용 증가와 백신 접종을 통한 인식 증진을 추진하는 정부의 대처가 시장 성장의 주요 요인이 되고 있습니다. 게다가 세계 공통 인플루엔자 백신을 개발하기 위한 주요 기업에 의한 연구개발 활동의 확대가 예측기간(2025-2032년)에 있어서 시장의 성장을 가속하고 있습니다.

인플루엔자 백신 시장 역학

미국 질병통제예방센터(CDC)에서 제공한 데이터에 따르면 2022-2023년 기간의 이환율은 팬데믹 이전 시즌과 비슷했으며, 약 3,100만 명이 인플루엔자에 감염되어 1,400만 건의 의료 서비스 상담과 36만 건의 독감 관련 병원 입원이 발생했습니다. 2024년 4월, 호주 질병통제센터에 따르면 2023년 한 해 동안 호주는 이미 37,700건 이상의 실험실 확진 사례를 기록했으며, 이는 작년 같은 기간에 비해 40% 증가한 수치입니다.

2023년 2월 캐나다 정부가 인플루엔자 백신 접종의 보급 상황을 조사하기 위해 실시한 Seasonal Influenza Vaccination Coverage Survey에 따르면, 인플루엔자 백신 접종률은 2021-2022년의 39%에서 2022-2023년에 43%로 증가해 팬데믹 이전 수준으로 회복했습니다. 백신 접종의 장소에는 현저한 변화가 보여 2019-2020년 시즌에 비해 약국(52%) 또는 임시 백신 클리닉(12%)에서 인플루엔자의 예방접종을 받기로 선택하는 성인의 비율이 높아지고 있습니다. 정부 기관은 인플루엔자 예방 접종이 독감을 예방하는 가장 효과적인 조치임을 강력하게 보여주고 예방 접종을 이용할 수 있도록 강력하게 지원합니다.

예를 들어 2023년 10월 대만 정부는 독감 예방 접종 캠페인을 시작했습니다. 정부는 정부 자금에 의한 4가 인플루엔자 백신 698만 회분의 접종을 계속해 전체 인구의 29.6%로 접종 범위를 확대했습니다.

2023년 10월, Pfizer와 BioNTech는 18세에서 64세 사이의 건강한 성인을 대상으로 인플루엔자와 COVID-19를 모두 대상으로 한 mRNA 기반 혼합 백신 후보의 안전성, 내성 및 면역 반응을 평가하는 1/2 임상시험의 좋은 초기 소견을 발표했습니다.

그러나, 백신 생산에 장기간이 소요되고 계절성 균주에 대한 유효성이 제한적이라는 것이 시장의 성장을 제한하는 주요 억제요인이 되고 있습니다.

인플루엔자 백신 시장의 부문 분석

유형별로는 2024년에 비활성 인플루엔자 백신 카테고리가 시장에서 큰 수익 점유율을 차지할 것으로 추정되었습니다. 이는 안전성과 효능이 높고 제조 비용이 낮기 때문에 불활성 인플루엔자 백신은 전 세계적으로 가장 높은 비율로 투여되고 있습니다. 세계보건기구(WHO)가 2024년에 발표한 조사에 따르면 알과 세포 배양액을 사용하여 제조된 불활화 백신은 2022년 계절성 인플루엔자 백신의 총량의 약 98%를 차지했습니다.

2023년 9월, Clover Biopharmaceuticals는 중국에서 AdimFlu-S(QIS)의 상시를 발표하고 3세 이상의 개인에게 투여가 허가된 4가 계절성 인플루엔자 백신의 출시를 시작했습니다. AdimFlu-S(QIS)는 인플루엔자 예방을 위한 4가 불활성화 스플릿 백신입니다. 이 백신은 2개의 A 균주와 2개의 B 균주를 포함하는 4개의 상이한 인플루엔자 바이러스 균주로부터 수득된 헤마글루티닌으로 구성됩니다.

이 보고서는 세계 인플루엔자 백신 시장에 대한 조사 분석을 통해 시장 규모와 예측, 지난 3년간 제품/기술 개발, 시장의 주요 기업, 이용 가능한 기회 등의 정보를 제공합니다.

목차

제1장 인플루엔자 백신 시장 보고서 서론

제2장 인플루엔자 백신 시장의 주요 요약

  • 시장 개요

제3장 경쟁 구도

제4장 규제 분석

  • 미국
  • 유럽
  • 일본
  • 중국

제5장 인플루엔자 백신 시장의 주요 요인 분석

  • 인플루엔자 백신 시장 성장 촉진요인
  • 인플루엔자 백신 시장 성장 억제요인과 과제
  • 인플루엔자 백신 시장의 기회

제6장 인플루엔자 백신 시장의 Porter's Five Forces 분석

제7장 인플루엔자 백신 시장 평가

  • 유형별
    • 불활성화 인플루엔자 백신
    • 재조합 인플루엔자 백신
    • 약독화 생 인플루엔자 백신
  • 가수별
    • 3가
    • 4가
  • 제조 공정별
    • 계란 기반 백신
    • 세포 배양 기반 백신
  • 투여 경로별
    • 비강
    • 전신
  • 유통 채널별
    • 병원, 약국
    • 정부기관
  • 지역별
    • 북미
    • 유럽
    • 아시아태평양
    • 기타 지역

제8장 인플루엔자 백신 시장의 기업 및 제품 프로파일

  • GSK plc
  • Pfizer Inc.
  • BioNTech
  • SINOVAC
  • Moderna, Inc.
  • Merck & Co., Inc.
  • Sanofi
  • AstraZeneca
  • CSL
  • Abbott
  • Novavax
  • Gilead Sciences, Inc.
  • Serum Institute Of India Pvt. Ltd.
  • DAIICHI SANKYO COMPANY, LIMITED
  • Novartis AG
  • Cadila Pharmaceuticals
  • Boehringer Ingelheim International GmbH
  • Zydus Pharmaceuticals, Inc.
  • Panacea Biotec
  • Bharat Biotech

제9장 KOL의 견해

제10장 프로젝트 접근법

제11장 DelveInsight 정보

제12장 면책사항 및 문의

KTH 25.03.04

Influenza Vaccine Market by Type (Inactivated Influenza Vaccine, Recombinant Influenza Vaccine, and Live Attenuated Influenza Vaccine), Valency (Trivalent, Quadrivalent), Manufacturing Process (Egg-based Vaccine, Cell Culture-based Vaccine), Route of Administration (Nasal, Systemic), Distribution Channel (Hospital and Retail Pharmacy, Government Agencies), Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to grow at a steady CAGR forecast till 2032 owing to the increasing prevalence of influenza and the rising adoption of influenza vaccine

The influenza vaccine market was valued at USD 8,247.44 million in 2024, growing at a CAGR of 6.87% during the forecast period from 2025 to 2032 to reach USD 13,950.82 million by 2032. The need for influenza vaccination is primarily driven by the increasing prevalence of influenza worldwide due to the spread of the virus through droplets transmitted via cough and sneezing. The rising adoption of the influenza vaccine and government initiatives to promote awareness through vaccination are the key factors contributing to the growth of the market. Furthermore, Growing R&D initiatives by key players to develop universal influenza vaccine are driving the influenza vaccine market growth during the forecast period (2025-2032)

Influenza Vaccine Market Dynamics:

According to data provided by the Centers for Disease Control and Prevention (CDC), the morbidity rate during the 2022 to 2023 period mirrored that of pre-pandemic seasons, with approximately 31 million individuals affected by influenza, resulting in 14 million healthcare provider consultations and 360,000 flu-related hospital admissions. In April 2024, according to Australian Center for Disease Control, for the year 2023, Australia had already recorded over 37,700 laboratory-confirmed cases, marking a 40% increase compared to the corresponding period last year.

In February 2023, according to Seasonal Influenza Vaccination Coverage Survey, which is conducted by Government of Canada to collect the adoption of vaccination for influenza, the influenza vaccination coverage saw a rise from 39% during the 2021-2022 period to 43% in 2022-2023, now returning to pre-pandemic levels. A notable shift was observed in the vaccination venues, with a higher proportion of adults opting to receive their flu shot in a pharmacy (52%) or at temporary vaccine clinics (12%) compared to the 2019-2020 season. Government entities strongly providing support to avail vaccination, highlighting that influenza vaccination stands as the most efficacious measure for preventing influenza.

For instance, in October 2023, the Taiwan government launched an influenza vaccination campaign. The government sustained the provision of 6.98 million doses of the quadrivalent government-funded influenza vaccine, extending coverage to 29.6% of the total population.

In October 2023, Pfizer Inc. and BioNTech announced favorable initial findings from a Phase 1/2 clinical trial assessing the safety, tolerance, and immune response of mRNA-based combination vaccine candidates targeting both influenza and COVID-19 in healthy adults aged 18 to 64 years.

However, the long period for vaccine production, and the limited efficacy against seasonal strains, among others are some of the key constraints that may limit the growth of the influenza vaccine market.

Influenza Vaccine Market Segment Analysis:

Influenza Vaccine Market by Type (Inactivated Influenza Vaccine, Recombinant Influenza Vaccine, and Live Attenuated Influenza Vaccine), Valency (Trivalent, Quadrivalent), Manufacturing Process (Egg-based Vaccine, Cell Culture-based Vaccine), Route of Administration (Nasal, Systemic), Distribution Channel (Hospital and Retail Pharmacy, Government Agencies), Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the type segment of the influenza vaccine market, the inactivated influenza vaccine category is estimated to generate a significant revenue share in the influenza vaccine market in 2024. This can be attributed to the high safety and efficacy and low manufacturing cost, due to this inactivated influenza vaccine has the highest percentage of administration across the globe. According to a study published by the World Health Organization in 2024, inactivated vaccines, manufactured using eggs or cell cultures, accounted for approximately 98% of the total volume of the 2022 seasonal influenza vaccine.

In September 2023, Clover Biopharmaceuticals, announced the launch of AdimFlu-S (QIS) in China, marking the availability of a quadrivalent seasonal influenza vaccine authorized for administration in individuals aged three years and above. AdimFlu-S (QIS) represents a quadrivalent split inactivated vaccine designed for influenza prevention. It comprises hemagglutinin sourced from four distinct influenza virus strains, encompassing two A strains and two B strains.

Inactivated vaccines exhibit greater stability and a lower propensity for mutation compared to live vaccines. This characteristic renders them a preferred option for transportation and storage, as they are less susceptible to temperature fluctuations. This vaccine has a high safety profile and stimulates the immune system to produce antibodies to protect against four strains of the virus.

Therefore, the high efficacy and safety and greater stability associated with the inactivated influenza vaccine category are estimated to contribute to the growth of the segment, thereby driving the growth of the overall influenza vaccine market during the forecast period.

North America is expected to dominate the overall Influenza Vaccine Market:

North America is expected to account for the highest market share of the influenza vaccine market in 2024. This is due to the rising number of influenza cases in the region and growing government support for vaccination programs. These are the factors contributing to the growth of the influenza vaccine market in North America.

According to the data provided by the Centers for Disease Control and Prevention (CDC) in February 2024, between 2010 and 2023, influenza has led to an annual range of 9.3 million to 41 million illnesses and 100,000 to 710,000 hospitalizations. In December 2023, as per the report shared by the Canadian government, in the 2021 to 2022 influenza season, there were 16,126 laboratory-confirmed influenza detections out of a total of 751,900 laboratory tests conducted.

Additionally, government organizations in the region are actively providing support to prevent and treat flu in the region. In 2024, the CDC disclosed the identification of an extra USD 93 million to bolster its ongoing response initiatives for avian influenza. This funding has been allocated for the purposes of influenza prevention and vaccination efforts.

In July 2022, GSK plc announced a partnership agreement with the Government of Canada aimed at providing pandemic and seasonal influenza vaccines to safeguard both Canadian adults and children. Under this contract, GSK provided up to 80 million doses of pandemic influenza vaccine to the Government of Canada in the event of influenza pandemics. Additionally, a total of 16 million doses of seasonal influenza vaccine will be supplied throughout the contract. These are some of the factors contributing to the growth of the influenza vaccine market in the region.

Influenza Vaccine Market Key Players:

Some of the key market players operating in the influenza vaccine market include GSK plc, Pfizer Inc., BioNTech, SINOVAC, Moderna, Inc., Merck & Co., Inc., Sanofi, AstraZeneca, CSL, Abbott, Novavax, Gilead Sciences, Inc., Serum Institute Of India Pvt. Ltd., DAIICHI SANKYO COMPANY, LIMITED, Novartis AG, Cadila Pharmaceuticals, Boehringer Ingelheim International GmbH, Zydus Pharmaceuticals, Inc., Panacea Biotec, Bharat Biotech, and others.

Recent Developmental Activities in the Influenza Vaccine Market:

  • In April 2024, CureVac SE, announced the commencement of Phase 1 for a collaborative venture with GSK marking the initiation of a combined Phase 1/2 investigation into an experimental pre-pandemic vaccine targeting influenza A (H5N1). This is a monovalent vaccine candidate based on mRNA technology and encodes an influenza A H5-antigen.
  • In October 2023, Moderna, Inc. announced the interim findings from the Phase 1/2 trial of mRNA-1083, a potential combination vaccine addressing both influenza and COVID-19, have been reported as favorable. mRNA-1083 showed a strong immunogenicity and safety profile against influenza.

Key Takeaways from the Influenza Vaccine Market Report Study

  • Market size analysis for current Influenza Vaccine Market size (2024), and market forecast for 8 years (2025-2032)
  • Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years
  • Key companies dominating the global Influenza Vaccine market.
  • Various opportunities available for the other competitors in the Influenza Vaccine Market space.
  • What are the top-performing segments in 2024? How these segments will perform in 2032?
  • Which are the top-performing regions and countries in the current Influenza Vaccine market scenario?
  • Which are the regions and countries where companies should have concentrated on opportunities for Influenza Vaccine market growth in the coming future?

Target Audience who can be benefited from this Influenza Vaccine Market Report Study

  • Influenza Vaccine product providers
  • Research organizations and consulting companies
  • Influenza Vaccine related organizations, associations, forums, and other alliances
  • Government and corporate offices
  • Start-up companies, venture capitalists, and private equity firms
  • Distributors and Traders dealing in Influenza Vaccine
  • Various end-users who want to know more about the Influenza Vaccine Market and the latest developments in the Influenza Vaccine Market.

FREQUENTLY ASKED QUESTIONS FOR THE INFLUENZA VACCINE MARKET:

1. What are Influenza Vaccine?

  • An influenza vaccine is a proactive solution aimed at mitigating the impact of influenza viruses. It comprises either inactivated or weakened strains of the virus, or its fragments, stimulating the body's immune response to produce antibodies. These antibodies serve as a defense mechanism against the virus upon subsequent exposure. Given the virus's tendency to mutate, necessitating regular updates, influenza vaccines are typically administered annually to maintain efficacy.

2. What is the market for Influenza Vaccine?

  • The influenza vaccine market was valued at USD 8,247.44 million in 2024, growing at a CAGR of 6.87% during the forecast period from 2025 to 2032 to reach USD 13,950.82 million by 2032.

3. What are the drivers for the global Influenza Vaccine market?

  • The need for influenza vaccination is primarily driven by the increasing prevalence of influenza worldwide due to the spread of the virus through droplets transmitted via cough and sneezing. The rising adoption of the influenza vaccine and government initiatives to promote awareness through vaccination are the key factors contributing to the growth of the market. Furthermore, Growing R&D initiatives by key players to develop universal influenza vaccine are driving the influenza vaccine market growth during the forecast period (2025-2032).

4. Who are the key players operating in the global Influenza Vaccine market?)

  • Some of the key market players operating in the influenza vaccine include GSK plc, Pfizer Inc., BioNTech, SINOVAC, Moderna, Inc., Merck & Co., Inc., Sanofi, AstraZeneca, CSL, Abbott, Novavax, Gilead Sciences, Inc., Serum Institute Of India Pvt. Ltd., DAIICHI SANKYO COMPANY, LIMITED, Novartis AG, Cadila Pharmaceuticals, Boehringer Ingelheim International GmbH, Zydus Pharmaceuticals, Inc., Panacea Biotec, Bharat Biotech, and others.

5. Which region has the highest share in the global Influenza Vaccine market?

  • North America is expected to account for the highest market share of the influenza vaccine market in 2024. This is due to the rising number of influenza cases in the region and growing government support for vaccination programs. These are the factors contributing to the growth of the influenza vaccine market in North America.

Table of Contents

1. Influenza Vaccine Market Report Introduction

  • 1.1. Scope of the Study
  • 1.2. Market Segmentation
  • 1.3. Market Assumption

2. Influenza Vaccine Market Executive Summary

  • 2.1. Market at Glance

3. Competitive Landscape

4. Regulatory Analysis

  • 4.1. The United States
  • 4.2. Europe
  • 4.3. Japan
  • 4.4. China

5. Influenza Vaccine Market Key Factors Analysis

  • 5.1. Influenza Vaccine Market Drivers
    • 5.1.1. Increasing Prevalence of Influenza
    • 5.1.2. The rising adoption of influenza vaccine
    • 5.1.3. Government initiatives to promote awareness through vaccination
    • 5.1.4. Growing R&D initiatives by key players
  • 5.2. Influenza Vaccine Market Restraints and Challenges
    • 5.2.1. Long period for vaccine production
    • 5.2.2. Limited efficacy against seasonal strains
  • 5.3. Influenza Vaccine Market Opportunity
    • 5.3.1. Need to develop faster production technology
    • 5.3.2. Constant drug discovery to develop universal vaccines

6. Influenza Vaccine Market Porter's Five Forces Analysis

  • 6.1. Bargaining Power of Suppliers
  • 6.2. Bargaining Power of Consumers
  • 6.3. Threat of New Entrants
  • 6.4. Threat of Substitutes
  • 6.5. Competitive Rivalry

7. Influenza Vaccine Market Assessment

  • 7.1. By Type
    • 7.1.1. Inactivated Influenza Vaccine
    • 7.1.2. Recombinant Influenza Vaccine
    • 7.1.3. Live Attenuated Influenza Vaccine
  • 7.2. By Valency
    • 7.2.1. Trivalent
    • 7.2.2. Quadrivalent
  • 7.3. By Manufacturing Process
    • 7.3.1. Egg-based Vaccine
    • 7.3.2. Cell Culture-based Vaccine
  • 7.4. By Route of Administration
    • 7.4.1. Nasal
    • 7.4.2. Systemic
  • 7.5. By Distribution Channel
    • 7.5.1. Hospitals and Retail Pharmacy
    • 7.5.2. Government Agencies
  • 7.6. By Geography
    • 7.6.1. North America
      • 7.6.1.1. United States Influenza Vaccine Market Size in USD million (2022-2032)
      • 7.6.1.2. Canada Influenza Vaccine Market Size in USD million (2022-2032)
      • 7.6.1.3. Mexico Influenza Vaccine Market Size in USD million (2022-2032)
    • 7.6.2. Europe
      • 7.6.2.1. France Influenza Vaccine Market Size in USD million (2022-2032)
      • 7.6.2.2. Germany Influenza Vaccine Market Size in USD million (2022-2032)
      • 7.6.2.3. United Kingdom Influenza Vaccine Market Size in USD million (2022-2032)
      • 7.6.2.4. Italy Influenza Vaccine Market Size in USD million (2022-2032)
      • 7.6.2.5. Spain Influenza Vaccine Market Size in USD million (2022-2032)
      • 7.6.2.6. Rest of Europe Influenza Vaccine Market Size in USD million (2022-2032)
    • 7.6.3. Asia-Pacific
      • 7.6.3.1. China Influenza Vaccine Market Size in USD million (2022-2032)
      • 7.6.3.2. Japan Influenza Vaccine Market Size in USD million (2022-2032)
      • 7.6.3.3. India Influenza Vaccine Market Size in USD million (2022-2032)
      • 7.6.3.4. Australia Influenza Vaccine Market Size in USD million (2022-2032)
      • 7.6.3.5. South Korea Influenza Vaccine Market Size in USD million (2022-2032)
      • 7.6.3.6. Rest of Asia-Pacific Influenza Vaccine Market Size in USD million (2022-2032)
    • 7.6.4. Rest of the World (RoW)
      • 7.6.4.1. Middle East Influenza Vaccine Market Size in USD million (2022-2032)
      • 7.6.4.2. Africa Influenza Vaccine Market Size in USD million (2022-2032)
      • 7.6.4.3. South America Influenza Vaccine Market Size In USD Million (2022-2032)

8. Influenza Vaccine Market Company and Product Profiles

  • 8.1. GSK plc
    • 8.1.1. Company Overview
    • 8.1.2. Company Snapshot
    • 8.1.3. Financial Overview
    • 8.1.4. Product Listing
    • 8.1.5. Entropy
  • 8.2. Pfizer Inc.
    • 8.2.1. Company Overview
    • 8.2.2. Company Snapshot
    • 8.2.3. Financial Overview
    • 8.2.4. Product Listing
    • 8.2.5. Entropy
  • 8.3. BioNTech
    • 8.3.1. Company Overview
    • 8.3.2. Company Snapshot
    • 8.3.3. Financial Overview
    • 8.3.4. Product Listing
    • 8.3.5. Entropy
  • 8.4. SINOVAC
    • 8.4.1. Company Overview
    • 8.4.2. Company Snapshot
    • 8.4.3. Financial Overview
    • 8.4.4. Product Listing
    • 8.4.5. Entropy
  • 8.5. Moderna, Inc.
    • 8.5.1. Company Overview
    • 8.5.2. Company Snapshot
    • 8.5.3. Financial Overview
    • 8.5.4. Product Listing
    • 8.5.5. Entropy
  • 8.6. Merck & Co., Inc.
    • 8.6.1. Company Overview
    • 8.6.2. Company Snapshot
    • 8.6.3. Financial Overview
    • 8.6.4. Product Listing
    • 8.6.5. Entropy
  • 8.7. Sanofi
    • 8.7.1. Company Overview
    • 8.7.2. Company Snapshot
    • 8.7.3. Financial Overview
    • 8.7.4. Product Listing
    • 8.7.5. Entropy
  • 8.8. AstraZeneca
    • 8.8.1. Company Overview
    • 8.8.2. Company Snapshot
    • 8.8.3. Financial Overview
    • 8.8.4. Product Listing
    • 8.8.5. Entropy
  • 8.9. CSL
    • 8.9.1. Company Overview
    • 8.9.2. Company Snapshot
    • 8.9.3. Financial Overview
    • 8.9.4. Product Listing
    • 8.9.5. Entropy
  • 8.10. Abbott
    • 8.10.1. Company Overview
    • 8.10.2. Company Snapshot
    • 8.10.3. Financial Overview
    • 8.10.4. Product Listing
    • 8.10.5. Entropy
  • 8.11. Novavax
    • 8.11.1. Company Overview
    • 8.11.2. Company Snapshot
    • 8.11.3. Financial Overview
    • 8.11.4. Product Listing
    • 8.11.5. Entropy
  • 8.12. Gilead Sciences, Inc.
    • 8.12.1. Company Overview
    • 8.12.2. Company Snapshot
    • 8.12.3. Financial Overview
    • 8.12.4. Product Listing
    • 8.12.5. Entropy
  • 8.13. Serum Institute Of India Pvt. Ltd.
    • 8.13.1. Company Overview
    • 8.13.2. Company Snapshot
    • 8.13.3. Financial Overview
    • 8.13.4. Product Listing
    • 8.13.5. Entropy
  • 8.14. DAIICHI SANKYO COMPANY, LIMITED
    • 8.14.1. Company Overview
    • 8.14.2. Company Snapshot
    • 8.14.3. Financial Overview
    • 8.14.4. Product Listing
    • 8.14.5. Entropy
  • 8.15. Novartis AG
    • 8.15.1. Company Overview
    • 8.15.2. Company Snapshot
    • 8.15.3. Financial Overview
    • 8.15.4. Product Listing
    • 8.15.5. Entropy
  • 8.16. Cadila Pharmaceuticals
    • 8.16.1. Company Overview
    • 8.16.2. Company Snapshot
    • 8.16.3. Financial Overview
    • 8.16.4. Product Listing
    • 8.16.5. Entropy
  • 8.17. Boehringer Ingelheim International GmbH
    • 8.17.1. Company Overview
    • 8.17.2. Company Snapshot
    • 8.17.3. Financial Overview
    • 8.17.4. Product Listing
    • 8.17.5. Entropy
  • 8.18. Zydus Pharmaceuticals, Inc.
    • 8.18.1. Company Overview
    • 8.18.2. Company Snapshot
    • 8.18.3. Financial Overview
    • 8.18.4. Product Listing
    • 8.18.5. Entropy
  • 8.19. Panacea Biotec
    • 8.19.1. Company Overview
    • 8.19.2. Company Snapshot
    • 8.19.3. Financial Overview
    • 8.19.4. Product Listing
    • 8.19.5. Entropy
  • 8.20. Bharat Biotech
    • 8.20.1. Company Overview
    • 8.20.2. Company Snapshot
    • 8.20.3. Financial Overview
    • 8.20.4. Product Listing
    • 8.20.5. Entropy

9. KOL Views

10. Project Approach

11. About DelveInsight

12. Disclaimer & Contact Us

비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제